Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Carcinoma, Non-Small-Cell Lung 11Carcinoma, Hepatocellular 7Colorectal Neoplasms 5Neoplasm Metastasis 4Esophageal Squamous Cell Carcinoma 4Advanced Solid Tumor 4Solid Tumor 3Small Cell Lung Carcinoma 3Esophageal Neoplasms 3Stomach Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Recurrence 2Melanoma 2Lung Neoplasms 2Cholangiocarcinoma 2Carcinoma, Transitional Cell 2Advanced Solid Tumour 2Unresectable Stage III Non-small Cell Lung Cancer 1Triple Negative Breast Neoplasms 1Skin Neoplasms 1Simpson-Golabi-Behmel syndrome 1Rectal Neoplasms 1Patients With Initially Unresectable MSS-type Advanced Colorectal Cancer With Liver and/or Lung and Peritoneal Metastasis 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Pancreatic Neoplasms 1Neoplasms 1Neoplasm, Residual 1Nasopharyngeal Carcinoma 1Metastatic Solid Tumors 1MSI-H/dMMR Solid Tumors 1

Interventions

pembrolizumab 36Bevacizumab 25Cyclophosphamide 22Blood Specimen Collection 18Nivolumab 17Carboplatin 15Standard of Care 14Paclitaxel 14atezolizumab 13Gemcitabine 13Exercise 13Pemetrexed 11Fluorouracil 11Doxorubicin 11Cisplatin 11Cetuximab 10Radiotherapy 9Oxaliplatin 9Magnetic Resonance Spectroscopy 9Leucovorin 9Docetaxel 9durvalumab 8abemaciclib 8Temozolomide 8Surveys and Questionnaires 8Rituximab 8Prednisone 8Biopsy 8130-nm albumin-bound paclitaxel 8olaparib 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasms × tislelizumab × 90 days × Clear all
NCT05516914 2026-04-01

A Phase Ib/II Clinical Trial of LBL-007 Combined With Tislelizumab in the Treatment of Malignant Tumors

Nanjing Leads Biolabs Co.,Ltd

Phase 1/2 Completed
98 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡